Clinical trials documenting the efficacy of low-dose glucocorticoids in rheumatoid arthritis

NeuroImmunoModulation

Volumn 22, Issue , 2014, Pages 46-50

  Pincus, Theodore ^a   Cutolo, Maurizio ^b  

^a RUSH UNIVERSITY   (United States)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Low dose prednisone; Prednisolone; Randomized clinical trials; Rheumatoid arthritis

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; METHOTREXATE; PLACEBO; PREDNISOLONE; PREDNISONE; GLUCOCORTICOID;

ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG EFFICACY; FUNCTIONAL STATUS; HUMAN; LONG TERM CARE; LOW DRUG DOSE; MORNING STIFFNESS; REMISSION; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; DOSE RESPONSE; FEMALE; MALE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; PREDNISONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84908594581     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000362734     Document Type: Article

References (34)

1. Hench PS, Kendall EC, Slocumb CH, Polley HF: The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of the pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 1949; 24: 181.
2. Streptomycin treatment of pulmonary tuberculosis: A Medical Research Council investigation. Br Med J 1948; 2: 769-782.
3. Hill AB: Suspended judgment: memories of the British streptomycin trial in tuberculosis - The first randomized clinical trial. Controlled Clin Trials 1990; 11: 77-79.
4. Hench PS: The reversibility of certain rheumatic and non-rheumatic conditions by the use of cortisone or of the pituitary adrenocorticotropic hormone. Ann Intern Med 1952; 36: 1-38.
5. Polley HF, Slocumb CH, Ward LE, Hench PS: Recognition and treatment of patients with chronic hypercortisonism. Ann Rheum Dis 1955; 14: 416-417.
6. Empire Rheumatism Council: Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis: results up to one year. Ann Rheum Dis 1955; 14: 353-367.
7. Empire Rheumatism Council: Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis: results of three years treatment. Ann Rheum Dis 1957; 16: 277-289.
8. Benedek TG: History of the development of corticosteroid therapy. Clin Exp Rheumatol 2011; 29(5 suppl 68):5-12.
9. de Andrade JR, McCormick JN, Hill AGS: Small doses of prednisolone in the management of rheumatoid arthritis. Ann Rheum Dis 1964; 23: 158-162.
10. Wolfe F, Hawley DJ: Remission in rheumatoid arthritis. J Rheumatol 1985; 12: 245-252.
11. Harris ED Jr, Emkey RD, Nichols JE, Newberg A: Low dose prednisone therapy in rheumatoid arthritis: A double blind study. J Rheumatol 1983; 10: 713-721.
12. Wassenberg S, Rau R, Steinfeld P, Zeidler H: Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, doubleblind, placebo-controlled trial. Arthritis Rheum 2005; 52: 3371-3380.
13. Kirwan JR: The effects of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 142-146.
14. Boers M, Verhoeven AC, Markusse HM, van de Laar MAFJ, Westhovens R, van Denderen JC, et al: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-318.
15. van Everdingen AA, Jacobs JWG, van Reesema DRS, Bijlsma JWJ: Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects. Ann Intern Med 2002; 136: 1-12.
16. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I: Low-dose prednisolone in addition to the initial diseasemodifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial. Arthritis Rheum 2005; 52: 3360-3370.
17. Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, et al: Low-dose prednisone inclusion in a methotrexate based, tight control strategy for early rheumatoid arthritis: A randomized trial. Ann Intern Med 2012; 156: 329-339.
18. Pincus T, Sokka T, Castrejón I, Cutolo M: Decline of mean initial prednisone dosage from 10.3 to 3.6 mg/day to treat rheumatoid arthritis between 1980 and 2004 in one clinical setting, with long-term effectiveness of dosages less than 5 mg/day. Arthritis Care Res 2013; 65: 729-736.
19. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al: Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA- 1): A double-blind, randomised controlled trial. Lancet 2008; 371: 205-214.
20. Pincus T, Swearingen CJ, Luta G, Sokka T: Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: A randomised, double- blind, placebo controlled withdrawal clinical trial. Ann Rheum Dis 2009; 68: 1715-1720.
21. Montecucco C, Todoerti M, Sakellariou G, Scire CA, Caporali R: Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther 2012; 14:R112.
22. Buttgereit F, Mehta D, Kirwan J, Szechinski J, Boers M, Alten RE, et al: Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomised clinical trial (CAPRA-2). Ann Rheum Dis 2013; 72: 204-210.
23. Pincus T, Callahan LF, Sale WG, Brooks AL, Payne LE, Vaughn WK: Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864-872.
24. Rasker JJ, Cosh JA: The natural history of rheumatoid arthritis: A fifteen year follow-up study. The prognostic significance of features noted in the first year. Clin Rheumatol 1984; 3: 11-20.
25. Scott DL, Grindulis KA, Struthers GR, Coulton BL, Popert AJ, Bacon PA: Progression of radiological changes in rheumatoid arthritis. Ann Rheum Dis 1984; 43: 8-17.
26. Yelin E, Meenan R, Nevitt M, Epstein W: Work disability in rheumatoid arthritis: effects of disease, social, and work factors. Ann Intern Med 1980; 93: 551-556.
27. Pincus T, Brooks RH, Callahan LF: Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994; 120: 26-34.
28. Landewé RB, Boers M, Verhoeven AC, Westhovens R, van De Laar MA, Markusse HM, et al: COBRA combination therapy in patients with early rheumatoid arthritis: longterm structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 347-356.
29. Pincus T, Castrejon I, Sokka T: Long-term prednisone in doses of less than 5 mg/day for treatment of rheumatoid arthritis: personal experience over 25 years. Clin Exp Rheumatol 2011; 29(5 suppl 68):S130-S138.
30. Pincus T, Sokka T, Kautiainen H: Patients seen for standard rheumatoid arthritis care have significantly better articular, radiographic, laboratory, and functional status in 2000 than in 1985. Arthritis Rheum 2005; 52: 1009-1019.
31. Pincus T, Bijlsma JW, Braun J, Buttgereit F, Cutolo M: Low-dose glucocorticoids in rheumatic diseases: introduction. Clin Exp Rheumatol 2011; 29(5 suppl 68):S2-S4.
32. Feinstein AR: An additional basic science for clinical medicine. II. The limitations of randomized trials. Ann Intern Med 1983; 99: 544- 550.
33. Kaptchuk TJ: The double-blind, randomized, placebo-controlled trial: gold standard or golden calf? J Clin Epidemiol 2001; 54: 541- 549.
34. Pincus T, Sokka T: Clinical trials in rheumatic diseases: designs and limitations. Rheum Dis Clin North Am 2004; 30: 701-724.